Pharma News
21 Dec 2025 to 27 Dec 2025
Dec 27, 2025
3 Pharmaceutical Stocks to Purchase at a Bargain Price | The Motley Fool
Novo Nordisk has received approval for a GLP-1 pill, expected to launch in early 2026, potentially regaining its lead in the weight loss market. Meanwhile, Eli Lilly continues to compete with attractive GLP-1 drugs. Out-of-favor companies like Bristol Myers Squibb, Merck, and Pfizer are also navigating patent cliffs and pipeline challenges, presenting investment opportunities amid market volatility.
Dec 27, 2025
GSK CEO: There's nothing quite like the joy of our medications succeeding - The Times
Emma Walmsley, the outgoing CEO of GlaxoSmithKline (GSK), reflects on her tenure, highlighting five major drug approvals in 2025 and a 33% rise in share price. GSK's focus on innovation and a successful split from its consumer division, Haleon, has revitalized the company. Walmsley leaves GSK poised for future growth, with a strong R&D pipeline and plans for significant investment in the U.S.
Dec 27, 2025
U.S. authorities give the green light to Wegovy pill for weight management - Times of Wayne County
U.S. regulators have approved Novo Nordisk's oral version of the weight-loss drug Wegovy, making it the first daily pill for obesity treatment. The pill, containing 25 mg of semaglutide, is expected to enhance access and reduce costs for patients. Rival Eli Lilly's orforglipron is still under review. Wegovy pills could be available within weeks, with a starting price of $149 per month.
Dec 27, 2025
NPPA sets retail prices for 37 newly approved medications, according to DrugsControl Media Services.
The National Pharmaceutical Pricing Authority (NPPA) has set the retail prices for 37 new drugs, including hypertensive and anti-diabetic medications, in accordance with the Drugs Prices Control Order (DPCO), 2013. This decision was made during a recent meeting held in New Delhi.
Dec 27, 2025
3 Pharmaceutical Stocks to Purchase at a Reduced Price - The Globe and Mail
Eli Lilly has overtaken Novo Nordisk in the GLP-1 drug market, but Novo Nordisk's recent approval for a GLP-1 pill could shift dynamics again. Investors are advised to consider Bristol Myers Squibb, Merck, and Pfizer, as they navigate patent cliffs and evolving drug pipelines. Novo Nordisk's stock rose following the pill approval, expected to launch in 2026.
Dec 27, 2025
Tirzepatide, dubbed the "King of Medications," Experiences a 70% Price Reduction, Revolutionizing Blood Sugar Management and ...
Eli Lilly's Tirzepatide, the world's best-selling drug, is expected to see a significant price drop after the 2025 medical insurance negotiations in China. New prices for Tirzepatide, effective January 2026, indicate reductions of up to 70%. This price cut is anticipated to reshape the market for GLP-1 drugs, which includes competitors like Novo Nordisk's semaglutide.
Dec 26, 2025
Nationwide Increase in Drug Seizures Reveals Extensive Use of Codeine Syrup and ...
Law enforcement agencies in India have launched coordinated operations across multiple states to combat the illegal trafficking of codeine-based cough syrups and psychotropic drugs. The recent surge in narcotic seizures underscores the widespread issue of drug diversion, prompting increased vigilance and enforcement efforts.
Dec 26, 2025
Eli Lilly and Novo Nordisk compete to secure a share of the obesity medication market in India - Medical Dialogues
Eli Lilly and Novo Nordisk are competing for dominance in India's obesity drug market, with Lilly's Mounjaro leading sales since its March launch. As patents on Novo's semaglutide expire in 2026, over 20 Indian firms plan to introduce generics. Both companies are investing in marketing and partnerships to expand their reach, with the market projected to exceed $1 billion in two years.
Dec 26, 2025
U.S. authorities authorize Wegovy tablet for weight management
U.S. regulators have approved Novo Nordisk's oral version of the weight-loss drug Wegovy, making it the first daily pill for obesity treatment. The pill, containing 25 mg of semaglutide, is expected to broaden access to obesity treatments. In trials, users lost an average of 13.6% of body weight, similar to injectable Wegovy. Eli Lilly's orforglipron is still under review.
Dec 26, 2025
As India's obesity drug market reaches US$70 million, a price competition intensifies.
Eli Lilly and Novo Nordisk are competing to dominate India's growing obesity drug market ahead of the arrival of cheaper generics in March. Novo is focusing on price cuts and rapid launches, while Lilly benefits from early market entry and celebrity endorsements. Analysts predict the Indian market could exceed $1 billion within two years, driven by rising obesity rates.
Dec 25, 2025
Wegovy receives FDA approval as the first oral medication for weight management - Longevity.Technology
The FDA has approved an oral version of Wegovy, Novo Nordisk's weight loss drug, marking a significant advancement in GLP-1 therapies for obesity. This pill offers a patient-friendly alternative to injections, expanding treatment options for the over 40% of US adults affected by obesity. The Wegovy pill is expected to be available in January, with pricing and insurance coverage still uncertain.
Dec 25, 2025
Reasons Behind the Nearly 14% Surge in Travere Therapeutics Stock on Wednesday
Travere Therapeutics' stock surged nearly 14% following positive analyst updates regarding its drug Filspari, which is under FDA review for treating focal segmental glomerulosclerosis (FSGS). Analysts suggest Filspari has blockbuster potential, with a decision expected by January 13, 2026. The company recently received full approval for Filspari to treat immunoglobulin A nephropathy (IgAN).
Dec 25, 2025
Thousands of Narcotic Injections Distributed Using Expired License, Reports DrugsControl Media Services
Authorities in Samastipur, Bihar, have dismantled a fake drug agency that was operating with an expired license. The agency was found supplying thousands of vials of narcotic injections, raising serious concerns about public safety and illegal pharmaceutical practices in the region.
Dec 25, 2025
GlobalData warns of impending patent expirations threatening the pharmaceutical sector worldwide.
The pharmaceutical industry faces a significant patent cliff, with only 4% of global drug sales expected to retain exclusivity by 2030, down from 12% in 2022. Key drugs like Merck’s Keytruda and Johnson & Johnson’s Darzalex/Faspro will lose US exclusivity by 2029, prompting companies to enhance lifecycle management strategies to mitigate revenue losses, according to GlobalData.
Dec 25, 2025
Amarin Calls on Supreme Court to Dismiss Review of Patent Dispute Over Skinny Label
Amarin Pharma Inc. has urged the U.S. Supreme Court to decline a review of a patent dispute involving Hikma Pharmaceuticals USA Inc. over "skinny labels" for generic drugs. Amarin argues the case lacks significant legal issues, while Hikma contends the ruling threatens the safety of skinny labels. The Supreme Court will consider the case on January 9.
Dec 25, 2025
U.S. authorities give the green light to Wegovy pill for weight management - Los Angeles Times
The FDA has approved Novo Nordisk's Wegovy pill, the first daily oral medication for obesity, expected to be available soon. This GLP-1 drug, containing 25 mg of semaglutide, offers a convenient alternative to injections. The pill could broaden access to obesity treatments, with a starting price of $149 per month, potentially reducing costs for patients.
Dec 24, 2025
Sanofi is set to purchase Dynavax, a company that produces hepatitis B vaccines, for $2.2 billion.
Sanofi is set to acquire U.S. vaccine company Dynavax Technologies for approximately $2.2 billion, enhancing its vaccine portfolio. The deal includes Dynavax's hepatitis B vaccine and an experimental shingles vaccine. Sanofi will pay $15.50 per share, a 39% premium. Additionally, the FDA declined to approve Sanofi's experimental drug tolebrutinib for multiple sclerosis.
Dec 24, 2025
Hims & Hers Encountered a GLP-1 Challenge This Year — However, Growth is Merely Slowing Down, Not Declining.
Hims & Hers faces scrutiny for selling compounded GLP-1 treatments, unapproved alternatives to Eli Lilly and Novo Nordisk's weight-loss drugs. The company's stock has dropped nearly 40% this quarter after losing a partnership with Novo Nordisk. Despite challenges, Hims & Hers aims for $725 million in GLP-1 revenue next year and plans global expansion. Analysts mostly recommend a 'Hold' on the stock.
Dec 24, 2025
FDA greenlights Wegovy pill, transforming the landscape of GLP-1 medications - HOLA
The FDA has approved the Wegovy pill, Novo Nordisk's first oral GLP-1 medication for weight loss, marking a significant advancement in obesity treatment. The pill, designed for convenience, shows promising results with an average weight loss of 16.6% in trials. It will be available in January, potentially reshaping obesity management and expanding access to treatment.
Dec 24, 2025
U.S. grants approval for pill form of Wegovy for weight loss | CBC.ca
The U.S. Food and Drug Administration has approved a pill version of Wegovy, Novo Nordisk’s popular weight loss drug, providing a more convenient alternative to the injectable formulation.
Dec 24, 2025
Medicare begins to allow coverage for popular weight loss medications - KSL TV
The Centers for Medicare and Medicaid Services announced a new program allowing some Medicare enrollees to access GLP-1 obesity drugs from Eli Lilly and Novo Nordisk for $50 a month. This initiative aims to improve health outcomes while controlling costs, with eligibility for about 10% of enrollees. The program will begin in July 2026, with further expansions planned.
Dec 24, 2025
Medicare begins to allow coverage for popular weight loss medications - METRO
Eli Lilly and Novo Nordisk will offer GLP-1 medications at reduced prices to state Medicaid programs, pending negotiations. As of October 1, 16 state Medicaid programs cover GLP-1s for obesity, but states like North Carolina and Michigan are limiting coverage due to high costs, according to KFF.
Dec 24, 2025
Sanofi is set to purchase Dynavax, a company that produces hepatitis B vaccines, for $2.2 billion - CNBC
The Trump administration has dropped the universal hepatitis B vaccination recommendation for infants, prompting backlash from the medical community. Dynavax's shares surged nearly 39% following Sanofi's acquisition announcement, which includes Dynavax's hepatitis B vaccine, Heplisav-B, and an experimental shingles vaccine. Meanwhile, Sanofi faced disappointment as the FDA rejected its multiple sclerosis drug tolebrutinib.
Dec 24, 2025
FDA greenlights daily pill for weight loss - CBS News
The U.S. Food and Drug Administration has approved a daily oral version of Wegovy, marking it as the first pill-form medication for obesity treatment. This approval highlights a significant advancement in weight loss options.
Dec 24, 2025
Increased Efforts to Combat Illegal Drugs and Cough Syrups Containing Codeine
Authorities in India are intensifying efforts to combat the illegal trade of narcotics, focusing on codeine-based cough syrups and other prescription drugs susceptible to abuse. The crackdown aims to curb misuse and ensure public safety.
Dec 24, 2025
Telangana DCA Conducts Raids on Mediblue Healthcare, Confiscates ₹1.70 Lakh in Unlicensed Goods
Telangana's Drugs Control Administration (DCA) raided Mediblue Healthcare Pvt. Ltd. on December 23, 2025, seizing unlicensed medical devices valued at ₹1.70 lakh. This operation highlights ongoing efforts to combat illegal manufacturing in the pharmaceutical sector.
Dec 24, 2025
Niagen Bioscience acquires complete rights to essential NAD+ patents in significant intellectual property development.
Niagen Bioscience has acquired a comprehensive patent portfolio from Queen’s University Belfast, securing sole ownership of key intellectual property related to nicotinamide riboside (NR) and its salt forms. This acquisition strengthens Niagen's position in the NR market, providing enhanced protection and control over its applications, including potential pharmaceutical uses, according to CEO Rob Fried.
Dec 24, 2025
Medicare begins to allow coverage for popular weight loss medications - AOL.com
Medicare beneficiaries may gain increased access to GLP-1 drugs like Wegovy for weight loss under a new voluntary model program, announced by the Centers for Medicare and Medicaid Services. Eligible enrollees will pay $50 monthly, with Medicare covering the rest. The initiative aims to improve health outcomes while controlling costs, benefiting about 10% of Medicare enrollees.
Dec 24, 2025
Medicare begins to allow coverage for popular weight loss medications - LocalNews8.com - KIFI
The Centers for Medicare and Medicaid Services announced a new program allowing eligible Medicare enrollees to access GLP-1 obesity drugs from Eli Lilly and Novo Nordisk for $50 a month. This initiative aims to improve health outcomes while controlling costs, with participation starting in July 2026. Approximately 10% of Medicare beneficiaries may qualify for this expanded access.
Dec 24, 2025
Medicare begins to allow coverage for popular weight loss medications | CNN Politics
The Centers for Medicare and Medicaid Services announced a new program allowing eligible Medicare enrollees to access GLP-1 obesity drugs from Eli Lilly and Novo Nordisk for $50 a month. This initiative aims to improve health outcomes while controlling costs, with participation starting in July 2026. The program addresses obesity as a chronic disease, benefiting about 10% of Medicare enrollees.
Dec 24, 2025
Looking Beyond Imports: Analyzing Patent Working Obligations and the Risk of Invalidation
Indonesia has enacted Law No. 65 of 2024, requiring all patent holders to submit annual "working" reports for active patents. This shift emphasizes public benefit over passive monopoly, aligning with global trends. Non-compliance may lead to patent invalidation. The law aims to enhance local manufacturing and access to essential medicines, potentially influencing other emerging economies.
Dec 24, 2025
The fierce competition between Lilly and Novo has opened up the market for weight-loss medications in India.
Ozempic, a once-weekly injection approved by the U.S. drug regulator in 2017 for Type 2 diabetes, has become a global bestseller and is increasingly used off-label for weight loss due to its appetite-suppressing effects.
Dec 23, 2025
Court Rejects Novo Nordisk's Request for Temporary Relief, Allowing Dr. Reddy's to Continue Semaglutide Exports
The Delhi High Court denied Novo Nordisk's request for an interim injunction against Dr. Reddy’s Laboratories (DRL) regarding Semaglutide, citing vulnerabilities in the patent's validity. The court allowed DRL to manufacture Semaglutide for export, emphasizing the balance of convenience favored DRL. Novo Nordisk's claims of novelty were deemed insufficient, and the suit patent faces serious challenges.
Dec 23, 2025
FDA grants approval for Wegovy, the first oral weight-loss medication approved as an alternative to injectable GLP-1 treatments.
U.S. regulators have approved Novo Nordisk's Wegovy pill, the first oral GLP-1 weight-loss medication, expected to enhance access to obesity treatment. The pill, containing 25 mg of semaglutide, shows similar efficacy to its injectable counterpart. Analysts predict sales could reach nearly $2 billion by 2030. Eli Lilly's competing obesity pill, orforglipron, is under review.
Dec 23, 2025
Weight loss medication receives approval in the fight against obesity - Michael West Media
The FDA has approved Novo Nordisk's oral version of Wegovy, a weight-loss pill containing 25 mg of semaglutide, making it the first daily medication for obesity. This approval gives Novo Nordisk an advantage over Eli Lilly's orforglipron, still under review. The pill is expected to enhance accessibility and affordability in obesity treatment, potentially benefiting millions of Americans.
Dec 23, 2025
US authorities greenlight Wegovy pill, marking the first oral treatment for obesity - The Guardian
The FDA has approved Novo Nordisk's oral version of Wegovy, a weight-loss pill containing 25mg of semaglutide, making it the first daily medication for obesity. This approval gives Novo Nordisk an advantage over Eli Lilly's orforglipron, which is still under review. The Wegovy pill is expected to broaden access to obesity treatments and may cost around $149 per month.
Dec 23, 2025
U.S. authorities give the green light to Wegovy pill for weight management - ABC News
U.S. regulators have approved a pill version of the weight-loss drug Wegovy, developed by Novo Nordisk, making it the first daily oral medication for obesity. The pill, containing 25 mg of semaglutide, is expected to broaden access to obesity treatments. Wegovy pills are anticipated to be available soon, with a starting price of $149 per month.
Dec 23, 2025
A recent study reveals that users of Ozempic and Wegovy are experiencing reduced grocery expenses alongside weight loss.
A recent study from Cornell University reveals that U.S. households using GLP-1 appetite suppressants like Ozempic and Wegovy reduced grocery spending by an average of 5.3% within six months. The decline was most significant in snacks and calorie-rich foods. The trend persisted for a year among consistent users, but spending reverted to previous levels for those who stopped the medication.
Dec 23, 2025
How Will the New Pricing Agreement with the Government Affect BMY's Sales?
Bristol Myers Squibb (BMY) has reached a pricing agreement with the U.S. government to provide Eliquis (apixaban) at no cost to Medicaid starting January 1, 2026. BMY will also donate over 7 tons of Eliquis' active ingredient to enhance supply-chain resilience. The deal includes discounts on other drugs and aims to stabilize BMY's revenue amid competition.
Dec 23, 2025
Wegovy by Novo Nordisk Receives FDA Approval as the First Oral GLP-1 Medication for Weight Management
The FDA has approved Novo Nordisk's oral version of Wegovy, a weight loss drug, providing a convenient alternative to injections. The pill, containing semaglutide and salcaprozate sodium, is effective for weight loss and cardiovascular risk reduction. It will launch in January 2024, priced at $150 per month. Other companies, like Eli Lilly, are also advancing oral obesity treatments.
Dec 23, 2025
Ajanta Pharma partners with Biocon to market generic semaglutide internationally - Mint
Ajanta has signed an agreement with Biocon to distribute generic semaglutide in 26 countries across Asia and Africa next year, following patent expirations. Ajanta will procure the semaglutide injectable pen from Biocon and distribute it under its own brand in 23 countries and semi-exclusively in three others.
Dec 23, 2025
ABBV or AZN: Which Pharmaceutical Stock Represents a Superior Investment Opportunity at This Time? - TradingView
AbbVie (ABBV) and AstraZeneca (AZN) are both leading pharmaceutical companies with diverse portfolios. AbbVie has seen growth from Skyrizi and Rinvoq, despite challenges from Humira's biosimilars. AstraZeneca benefits from a broad range of blockbusters and expects significant revenue growth by 2030. While both companies are strong, AstraZeneca currently holds a slight advantage in investment potential.
Dec 23, 2025
Approval of Oral Wegovy paves the way for a new direction in the development of blockbuster medications - R&D World
The FDA has approved Novo Nordisk's oral Wegovy, a significant advancement in obesity treatment, showing similar weight loss to its injectable counterpart. The pill, available by prescription in January, requires specific dosing instructions. Meanwhile, Eli Lilly's orforglipron, a potential competitor, is expected to enter the market in 2026, marking a shift towards small-molecule GLP-1 therapies.
Dec 23, 2025
Exploring the Key 'Picks and Shovels' Investment in the Biotech Revolution: An In-Depth Look at West ...
West Pharmaceutical Services (NYSE: WST) has emerged as a key player in the evolving pharmaceutical landscape, focusing on specialized delivery systems for high-demand GLP-1 therapies and biologics. In Q3 2025, WST reported net sales of $804.6 million, driven by its High-Value Products segment. The company is set to launch its West Synchrony™ PFS System in 2026, aiming to enhance its market presence.
Dec 23, 2025
Novo Nordisk or Amgen: Which Healthcare Investment Is the Better Option?
Novo Nordisk (NVO) and Amgen (AMGN) are competing healthcare leaders, with NVO focusing on diabetes and obesity treatments through its semaglutide drugs, Ozempic, Rybelsus, and Wegovy. In contrast, AMGN diversifies across multiple therapeutic areas, including its obesity candidate MariTide. Recent challenges for NVO include competition from Eli Lilly, while AMGN shows stronger growth potential and stability, making it a more appealing investment.
Dec 23, 2025
FDA grants approval for Novo Nordisk's Wegovy weight loss medication - OODAloop
The FDA has approved Wegovy, Novo Nordisk's oral version of its popular weight loss drug, marking the first pill form of a GLP-1 medication for weight loss. The Wegovy pill is expected to be widely available in January. Eli Lilly's similar pill is anticipated for approval soon. GLP-1 drugs, including semaglutide and tirzepatide, have gained popularity for weight loss.
Dec 23, 2025
US grants approval for oral formulation of popular weight-loss medication Wegovy - Euronews.com
The FDA has approved Novo Nordisk's oral version of Wegovy, a daily pill for obesity treatment containing 25 mg of semaglutide, marking a significant advancement in weight-loss medications. This approval positions Novo Nordisk ahead of Eli Lilly, whose orforglipron is still under review. The Wegovy pill is expected to enhance accessibility and affordability in obesity treatment.
Dec 23, 2025
Is the Wegovy weight-loss medication effective in preventing obesity? - Firstpost
The FDA has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 weight-loss drug, to be taken daily on an empty stomach. The pill, containing semaglutide, is set to launch in January 2024. Clinical trials showed a 16.6% average weight loss after 64 weeks. The Wegovy pill aims to provide a more convenient alternative to injectable weight-loss medications.
Dec 23, 2025
Overview: Developers of weight-loss medications are positioning themselves to enter a profitable market as competition intensifies.
The weight-loss drug market is booming, projected to reach $150 billion in annual sales within a decade. Novo Nordisk's Wegovy, now available as a pill, leads the sector. Other companies like Eli Lilly, Pfizer, and Roche are advancing their own treatments, including Lilly's eloralintide and Pfizer's MET-097i, as competition intensifies in this lucrative market.
Dec 23, 2025
Significant Discoveries of Codeine Syrup and Prohibited Tablets Linked to Smuggling and Illegal Distribution
Authorities in northern India have intensified efforts against the illegal smuggling of codeine-based cough syrups and banned narcotics. Recent operations revealed forged licenses and interstate networks involved in the illicit trade, leading to significant seizures. Enforcement Directorate raids targeted de-addiction centers in Punjab and Maharashtra as part of the crackdown.
Dec 23, 2025
Seven Biopharmaceutical Trends to Monitor in 2026 - Genetic Engineering and Biotechnology News
Analysts at William Blair predict a positive outlook for the biopharma industry in 2026, citing stock recoveries and favorable policies from President Trump’s administration. Key players like Pfizer and Merck & Co. are investing heavily in U.S. manufacturing, while advancements in AI and cancer therapies, including Pfizer's PF-08634404, are expected to drive growth.
Dec 23, 2025
MannKind Corporation Reveals FDA Authorization of FUROSCIX® for Use in Children and ...
MannKind Corporation announced FDA approval for FUROSCIX® (furosemide) On-body Infusor for pediatric patients weighing 43 kg or more, expanding its use beyond adults. Additionally, five new patents were issued for the FUROSCIX ReadyFlow™ Autoinjector, which aims to provide rapid, home-based treatment for edema in adults. The autoinjector's FDA review is ongoing, with a target action date of July 26, 2026.
Dec 23, 2025
MannKind (MNKD) receives FDA approval for pediatric use and secures five patents for FUROSCIX - Stock Titan
MannKind Corporation announced the FDA approval of FUROSCIX® (furosemide) On-body Infusor for pediatric patients weighing 43 kg or more. Additionally, five new patents for the FUROSCIX ReadyFlow™ Autoinjector were issued, enhancing its intellectual property protection. The autoinjector, currently under FDA review, aims to provide rapid, at-home treatment for edema in adults with chronic heart failure or kidney disease.
Dec 23, 2025
OneSource CEO predicts that injectable medications will remain the leading choice for weight-loss treatments - CNBC TV18
Neeraj Sharma, CEO of OneSource Specialty Pharma, praised a Delhi High Court ruling permitting the manufacturing and export of semaglutide, an anti-diabetic and weight-loss drug, to non-patented countries. He believes this decision will significantly benefit the Indian pharmaceutical industry, reinforcing the dominance of injectables in the weight-loss drug market.
Dec 23, 2025
New Pricing Regulations for Patented Medicines by the PMPRB Set to Begin on January 1, 2026
Effective January 1, 2026, Canada's Patented Medicine Prices Review Board (PMPRB) will implement new Guidelines for monitoring patented medicine prices. The two-step review process aims to enhance efficiency and predictability, focusing on price comparisons with the Highest International Price (HIP) and Consumer Price Index (CPI). Existing medicines will undergo a two-year transition before reviews commence.
Dec 23, 2025
Pharmaceutical exports experience a 21% increase in November, according to DrugsControl Media Services.
India's pharmaceutical exports surged by 20.91% in November 2025, with a Year-over-Year growth of approximately 6.50% for the first eight months of the fiscal year. This significant increase highlights the robust performance of the country's drug and pharmaceutical sector.
Dec 23, 2025
Biofabri and Bharat Biotech sign a technology transfer deal to enhance worldwide availability of MTBVAC.
Biofabri and Bharat Biotech have signed a Technology Transfer Agreement to enhance global access to MTBVAC, a vaccine aimed at combating tuberculosis. This collaboration aims to leverage Bharat Biotech's expertise in vaccine manufacturing to improve distribution and availability of MTBVAC worldwide.
Dec 23, 2025
5 Major Pharmaceutical Stocks Likely to Excel in 2026 - TradingView
The drug and biotech sector has rebounded, with major companies like Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Amgen (AMGN), and AstraZeneca (AZN) showing strong performance. Eli Lilly's Mounjaro and Zepbound drive growth, while J&J and AbbVie expand their portfolios. Despite challenges, innovation and M&A activity signal a positive outlook for 2026.
Dec 23, 2025
US authorities give the green light to Wegovy pill for weight management - Upper Michigan's Source
U.S. regulators have approved Novo Nordisk's oral version of the weight-loss drug Wegovy, making it the first daily pill for obesity treatment. The pill, containing 25 mg of semaglutide, is expected to enhance access and affordability in obesity care. Rival Eli Lilly's orforglipron is still under review. Wegovy pills are anticipated to be available soon, with a starting cost of $149 per month.
Dec 22, 2025
Roche CEO calls on Switzerland to increase funding for new medications following agreement in the US - Bilyonaryo
Roche's CEO, Thomas Schinecker, urged Switzerland to increase drug prices to align with U.S. rates, emphasizing the potential impact on the Swiss pharmaceutical industry. Roche's U.S. subsidiary, Genentech, has agreed to "Most Favoured Nation" pricing under President Trump's initiative to lower drug costs. Roche plans to invest $50 billion in the U.S. over five years amid ongoing negotiations on tariffs.
Dec 22, 2025
Samsung Biologics plans to acquire a GSK pharmaceutical facility in the United States for $280 million, according to Nikkei Asia.
Samsung Biologics is acquiring its first U.S. drug production facility from GSK for $280 million to meet U.S. market demand. The acquisition includes a 100% stake in Human Genome Sciences in Maryland, with plans for capacity expansion and technology upgrades. The deal's value may change by its expected closure in early 2026.
Dec 22, 2025
The Impact of Data Exclusivity on India's Generic Pharmaceutical Sector - Vajiram & Ravi
The Indian government is collaborating with the Commerce Ministry, DPIIT, pharmaceuticals department, and health ministry to explore the implementation of data exclusivity. This initiative is tied to trade negotiations and aims to enhance intellectual property protections to attract significant foreign investment.
Dec 22, 2025
Korean pharmaceutical associations caution that price reforms could lead to a reduction of 3.6 trillion won and result in job losses - CHOSUNBIZ
The Emergency Response Committee for Drug Pricing Reform, representing five industry groups, has urged the South Korean government to reconsider its drug pricing reform plan, which aims to reduce generic drug prices from 53.55% to 40% of original drug prices. The committee warns this could lead to annual revenue losses of 3.6 trillion won and significant job cuts in the pharmaceutical sector.
Dec 22, 2025
Sign Up Today for Generic Medicines and Generic Medicine - GlobeNewswire
ResearchAndMarkets.com has announced a training course on "Patent Strategies for Generic Medicines" scheduled for March 17, 2026. The course aims to equip professionals with essential skills in navigating patent landscapes, conducting Freedom to Operate analyses, and understanding Supplementary Protection Certificates (SPCs). Expert trainers will provide insights into managing blocking patents and recent EPO case law.
Dec 22, 2025
PU Vice-Chancellor Prof Renu Vig Publishes Book Focused on Nanomaterials in Food and Pharmaceuticals
Panjab University Vice Chancellor Prof Renu Vig launched a book titled “Engineered Nanomaterials in Food and Drugs: From laboratory to market,” authored by Dr. Nishima Wangoo. The book explores the applications and advancements of nanomaterials, addressing ethical considerations in cancer theranostics and neurodegenerative disorders. Dr. Wangoo is recognized for her contributions to nanoscience.
Dec 22, 2025
Is it Time to Move On from Novo Nordisk and Invest in This Exceptional High-Yield Pharmaceutical Stock?
Novo Nordisk's shares have plummeted over two-thirds since mid-2024 despite being first in the GLP-1 weight loss market, overshadowed by Eli Lilly's successful drugs, Zepbound and Mounjaro. Meanwhile, Pfizer is aggressively pursuing growth in the GLP-1 space, acquiring Metsera and partnering with a Chinese company. Pfizer's lower valuation may present a contrarian investment opportunity compared to Novo Nordisk.
Dec 22, 2025
The Pfizer Transformation: An In-Depth Analysis of PFE's Financial Comeback and Strategic Renewal for 2025
Pfizer Inc. (NYSE: PFE) is navigating a challenging phase post-COVID-19, with a stock price down 45-50% from its 2021 peak. The company is pivoting towards oncology following its $43 billion Seagen acquisition, while facing competition in obesity from Eli Lilly and Novo Nordisk. Despite a high dividend yield, concerns over patent expirations loom ahead.
Dec 22, 2025
AZN and Daiichi's Enhertu Receives Breakthrough Designation for Broader Cancer Application - TradingView
AstraZeneca (AZN) and Daiichi Sankyo announced that the FDA has granted Breakthrough Therapy designation to their antibody-drug conjugate, Enhertu, for expanded use in treating HER2-positive early breast cancer. This marks the tenth BTD for Enhertu, highlighting its potential in combating disease recurrence. Additionally, AstraZeneca's phase III LATIFY study for ceralasertib in lung cancer did not meet its primary endpoint.
Dec 22, 2025
FDA Greenlights Cytokinetics' Heart Medication, Competing with Rapidly Expanding BMS Treatment
Cytokinetics has received FDA approval for its obstructive hypertrophic cardiomyopathy drug, Myqorzo (aficamten), which features less restrictive safety requirements compared to Bristol Myers Squibb's Camzyos. Myqorzo's label allows for more flexible monitoring and does not require drug-drug interaction screening. The drug is set to launch in January, with ongoing trials to expand its indications.
Dec 22, 2025
FDA grants approval for Novo Nordisk's Wegovy weight loss medication - NBC News
The FDA has approved the Wegovy pill, Novo Nordisk's oral version of its weight loss drug, marking a significant advancement in GLP-1 treatments. The pill, which must be taken daily, showed comparable weight loss results to the injectable version. Novo Nordisk plans to make it widely available in January, with production increased to prevent shortages.
Dec 21, 2025
Research Investigates How Neuroinflammation Contributes to Increased Nerve Damage in Progressive Conditions...
A recent study has revealed that neuroinflammation significantly worsens nerve damage in progressive multiple sclerosis (MS), an autoimmune condition affecting myelin. The research underscores the critical role of inflammation in advancing neurological impairments, suggesting that further exploration could lead to new therapeutic strategies for managing MS progression.
Dec 21, 2025
Court rejects request for discharge from 'fraudulent' Ayurvedic product creator, DrugsControl Media Services
A special court in Mumbai has dismissed the discharge pleas of doctors accused of prescribing a fraudulent Ayurvedic product promoted by self-proclaimed "miracle doctor" Munir. The court emphasized that medical professionals must provide accurate diagnoses, reinforcing accountability in the healthcare sector.
Dec 21, 2025
Arrests Made in Haryana for Unlicensed Medical Practices; Illegal Laboratories Threaten Health in Tribal Areas of Madhya Pradesh
Authorities in Haryana have arrested individuals involved in unqualified medical practices, highlighting the ongoing issue of illegal diagnostic facilities. Reports indicate that unauthorized pathology labs and X-ray centers in tribal regions of Madhya Pradesh pose significant health risks to the community. The crackdown aims to ensure patient safety and uphold medical standards.
Dec 21, 2025
Understanding data exclusivity and its potential impact on the accessibility of affordable generic medications due to government initiatives.
The Indian government is contemplating the implementation of "data exclusivity" in the pharmaceutical sector, which could impact the generics market. This provision would grant innovator companies exclusive rights over clinical trial data, potentially delaying generic drug entry and affecting India's competitive edge. Recent meetings with industry stakeholders, including Union Commerce Minister Piyush Goyal, have focused on how to implement this change.
Dec 21, 2025
Counterfeit Medications Valued at 50 Lakh Seized from the Home of a Medical Store Owner in ...
The FDA in Chhattisgarh seized approximately 200 cartons of counterfeit medicines worth ₹50 lakh from a medical store owner's residence in Sarangarh-Bilaigarh district. This operation marks a significant effort to combat the counterfeit drug trade in the region.
